trending Market Intelligence /marketintelligence/en/news-insights/trending/O1JmLybAVXKJP_jktxd5JQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Elpiscience Biopharmaceuticals secures $100M in series B round

Essential Energy Insights July 2020 - Issue 2

As COVID-19 Wears On, Regulators Examine Moratorium Extensions, Cost Recovery

Q&A Credit Risk Perspectives Series: COVID-19 Credit Risks and Recovery for Supply Chains

Assessing ESG Profiles And Returns Against The Broader High-Yield Sector

Elpiscience Biopharmaceuticals secures $100M in series B round

Chinese biopharmaceutical research and development company Elpiscience Biopharmaceuticals Co. Ltd. raised $100 million in a series B funding round led by Hyfinity Investments.

Tencent, GTJA Investment Group, Dyee Capital, Oriza Holdings, Ming Bioventures, WisdoMont and Parkway Global are among those who participated in the round, including current investors such as Lilly Asia Ventures, Hillhouse Capital Group and CDH Investments.

The cancer immunotherapy-focused company will mainly use the capital to advance immunotherapy candidates through pre-clinical and clinical development, as well as to broaden its product pipeline.

Elpiscience Biopharmaceuticals also entered into a partnership with Bank of China and Agricultural Bank of China for a 150 million Chinese yuan fund that will be used to build its good manufacturing practice capabilities.

As of Dec. 27, US$1 was equivalent to 7.00 Chinese yuan.